Alebund Pharmaceuticals (Jiangsu) announced that the first participant has been randomized and dosed in its global Phase IIb multi-regional clinical trial. With no efficacy/safety data yet, this is an early development milestone that slightly improves near-term visibility on the program’s progress.
Alebund Pharmaceuticals (Jiangsu) announced that the first participant has been randomized and dosed in its global Phase IIb multi-regional clinical trial. With no efficacy/safety data yet, this is an early development milestone that slightly improves near-term visibility on the program’s progress.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.12
